158 related articles for article (PubMed ID: 32051609)
1. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer.
Clark DF; Michalski ST; Tondon R; Nehoray B; Ebrahimzadeh J; Hughes SK; Soper ER; Domchek SM; Rustgi AK; Pineda-Alvarez D; Anderson MJ; Katona BW
Genet Med; 2020 May; 22(5):840-846. PubMed ID: 32051609
[TBL] [Abstract][Full Text] [Related]
2. Cancer predisposition and germline CTNNA1 variants.
Lobo S; Benusiglio PR; Coulet F; Boussemart L; Golmard L; Spier I; Hüneburg R; Aretz S; Colas C; Oliveira C
Eur J Med Genet; 2021 Oct; 64(10):104316. PubMed ID: 34425242
[TBL] [Abstract][Full Text] [Related]
3. First estimates of diffuse gastric cancer risks for carriers of
Coudert M; Drouet Y; Delhomelle H; Svrcek M; Benusiglio PR; Coulet F; Clark DF; Katona BW; van Hest LP; van der Kolk LE; Cats A; van Dieren JM; Nehoray B; Slavin T; Spier I; Hüneburg R; Lobo S; Oliveira C; Boussemart L; Masson L; Chiesa J; Schwartz M; Buecher B; Golmard L; Bouvier AM; Bonadona V; Stoppa-Lyonnet D; Lasset C; Colas C
J Med Genet; 2022 Dec; 59(12):1189-1195. PubMed ID: 36038258
[TBL] [Abstract][Full Text] [Related]
4. Frequency of
Guerra J; Pinto C; Pinto P; Pinheiro M; Santos C; Peixoto A; Escudeiro C; Barbosa A; Porto M; Francisco I; Lopes P; Isidoro AR; Cunha AL; Albuquerque C; Claro I; Oliveira C; Silva J; Teixeira MR
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686589
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of CTNNA1 germline mutations in asymptomatic carriers.
Benusiglio PR; Colas C; Guillerm E; Canard A; Delhomelle H; Warcoin M; Bellanger J; Eyries M; Zizi M; Netter J; Soubrier F; Parc Y; Mourregot A; Maran Gonzalez A; Cusin V; Denis JA; Coupier I; Svrcek M; Coulet F
Gastric Cancer; 2019 Jul; 22(4):899-903. PubMed ID: 30515673
[TBL] [Abstract][Full Text] [Related]
6. Hereditary diffuse gastric cancer - pathophysiology and clinical management.
Pinheiro H; Oliveira C; Seruca R; Carneiro F
Best Pract Res Clin Gastroenterol; 2014 Dec; 28(6):1055-68. PubMed ID: 25439071
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to gastric cancer.
Petrovchich I; Ford JM
Semin Oncol; 2016 Oct; 43(5):554-559. PubMed ID: 27899187
[TBL] [Abstract][Full Text] [Related]
8. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
Majewski IJ; Kluijt I; Cats A; Scerri TS; de Jong D; Kluin RJ; Hansford S; Hogervorst FB; Bosma AJ; Hofland I; Winter M; Huntsman D; Jonkers J; Bahlo M; Bernards R
J Pathol; 2013 Mar; 229(4):621-9. PubMed ID: 23208944
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and cancer risk in families with pathogenic
Xicola RM; Li S; Rodriguez N; Reinecke P; Karam R; Speare V; Black MH; LaDuca H; Llor X
J Med Genet; 2019 Dec; 56(12):838-843. PubMed ID: 31296550
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
[TBL] [Abstract][Full Text] [Related]
11. Role of germline aberrations affecting
Weren RDA; van der Post RS; Vogelaar IP; van Krieken JH; Spruijt L; Lubinski J; Jakubowska A; Teodorczyk U; Aalfs CM; van Hest LP; Oliveira C; Kamping EJ; Schackert HK; Ranzani GN; Gómez García EB; Hes FJ; Holinski-Feder E; Genuardi M; Ausems MGEM; Sijmons RH; Wagner A; van der Kolk LE; Cats A; Bjørnevoll I; Hoogerbrugge N; Ligtenberg MJL
J Med Genet; 2018 Oct; 55(10):669-674. PubMed ID: 29330337
[TBL] [Abstract][Full Text] [Related]
12. Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
Laitman Y; Nielsen SM; Bernstein-Molho R; Heald B; Hatchell KE; Esplin ED; Friedman E
Breast Cancer Res Treat; 2022 Nov; 196(2):355-361. PubMed ID: 36094610
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer.
Donner I; Kiviluoto T; Ristimäki A; Aaltonen LA; Vahteristo P
Fam Cancer; 2015 Jun; 14(2):241-6. PubMed ID: 25576241
[TBL] [Abstract][Full Text] [Related]
14. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC).
Lo W; Zhu B; Sabesan A; Wu HH; Powers A; Sorber RA; Ravichandran S; Chen I; McDuffie LA; Quadri HS; Beane JD; Calzone K; Miettinen MM; Hewitt SM; Koh C; Heller T; Wacholder S; Rudloff U
J Med Genet; 2019 Jun; 56(6):370-379. PubMed ID: 30745422
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y
Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience.
Calvello M; Marabelli M; Gandini S; Marino E; Bernard L; Dal Molin M; Di Cola G; Zanzottera C; Corso G; Fazio N; Gervaso L; Fumagalli Romario U; Barberis M; Guerrieri-Gonzaga A; Bertario L; Serrano D; Bonanni B
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239438
[TBL] [Abstract][Full Text] [Related]
17. Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes.
Garcia-Pelaez J; Barbosa-Matos R; São José C; Sousa S; Gullo I; Hoogerbrugge N; Carneiro F; Oliveira C
Eur J Med Genet; 2022 Jan; 65(1):104401. PubMed ID: 34871783
[TBL] [Abstract][Full Text] [Related]
18. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
[TBL] [Abstract][Full Text] [Related]
19. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
20. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
